Copenhagen, Denmark - 10 May 2011 - Topotarget A/S (NASDAQ OMX: TOPO.CO)
announced today the company's interim report for the period 1 January to 31
March 2011.

-- Topotarget recognized revenues of DKK 31.2 million during the period (DKK
29.2 million in the same period 2010)

-- A pre-tax loss of DKK 3.8 million (2010: Profit of DKK 23.6 million) was
recorded for the period

-- The Group's net cash and cash equivalents as of 31 March 2011 totaled DKK
176.3 million (DKK 287.5 million in the same period 2010)

-- Topotarget are still expecting a pre-tax loss of DKK 20-40 million for 2011
(excluding potential milestones)

The whole report is attached as a PDF-file or can be found on Topotarget's
website.


Topotarget A/S


For further information, please contact:

Francois Martelet, CEO: Direct: +45 39 17 83 41; Mobile: +45 51
32 83 41

Anders Vadsholt, CFO Direct: +45 39 17 83 45; Mobile: +45 28
98 90 55

Annette Lykke, IR Direct: +45 39 17 83 44; Mobile: +45
23 28 98 14



Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO.CO) is an international biotech company
headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti-neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of other chemotherapeutic agents, and is currently in a pivotal trial
within PTCL (peripheral T-cell lymphoma) and phase II in cancer of other
unknown primary site (CUP). Topotarget's cancer drug targets are HDAC, NAD+,
and topoisomerase II. Totect® is a product on the market developed from
Topotarget's drug discovery technology. Totect® is marketed by the company's
own sales specialists in the US. For more information, please refer to
www.topotarget.com.

Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrollment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.